- Conference to take place both in-person in Washington D.C. and virtually November 10-14, 2021
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that three abstracts about the Company’s allogeneic CAR T therapy programs will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in Washington D.C. and virtually November 10-14, 2021. Posters will include additional information on Celyad’s multiplexing capabilities using short hairpin RNA (shRNA) technology, the Company’s first allogeneic, IL-18-armored CAR T candidate, CYAD-203, and the Phase 1b KEYNOTE-B79 trial of CYAD-101 in refractory metastatic colorectal cancer patients.
Poster Presentation Details:
The following abstract titles published today are now available on the SITC website. Following the presentation at the meeting, the posters will be available in the Scientific Publications section of Celyad Oncology’s website.
Title: Evolving mutliplexed shRNA to generate tailored CAR T cell therapy
Date and Time: ePoster available starting 7 a.m. ET, November 12, 2021
Abstract Number: 146
Title: Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity
Date and Time: ePoster available starting 7 a.m. ET, November 12, 2021
Abstract Number: 107
Title: A Phase 1b KEYNOTE-B79 trial evaluating non-gene edited allogeneic CAR T-cells, CYAD-101, post FOLFOX preconditioning, followed by pembrolizumab, in refractory metastatic colorectal cancer patients
Date and Time: ePoster available starting 7 a.m. ET, November 12, 2021
Abstract Number: 407
